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Chronic inflammation and oxidative stress (OS) are present in Alzheimer’s disease (AD)
brains in addition to neuronal loss, Amyloid-β (Aβ) plaques and hyperphosphorylated
tau-protein neurofibrillary tangles (NFTs). Previously we showed that levels of the
pro-inflammatory cytokine, interleukin-18 (IL-18), are elevated in post-mortem AD brains.
IL-18 can modulate the tau kinases, Cdk5 and GSK3β, as well as Aβ-production.
IL-18 levels are also increased in AD risk diseases, including type-2 diabetes and
obesity. Here, we explored other IL-18 regulated proteins in neuron-like SH-SY5Y
cells. Differentiated SH-SY5Y cells, incubated with IL-18 for 24, 48, or 72 h, were
analyzed by two-dimensional gel electrophoresis (2D-DIGE). Specific altered protein spots
were chosen and identified with mass spectrometry (MS) and verified by western
immunoblotting (WIB). IL-18 had time-dependent effects on the SH-SY5Y proteome,
modulating numerous protein levels/modifications. We concentrated on those related
to OS (DDAH2, peroxiredoxins 2, 3, and 6, DJ-1, BLVRA), Aβ-degradation (MMP14,
TIMP2), Aβ-aggregation (Septin-2), and modifications of axon growth and guidance
associated, collapsin response mediator protein 2 (CRMP2). IL-18 significantly increased
antioxidative enzymes, indicative of OS, and altered levels of glycolytic α- and γ-enolase
and multifunctional 14-3-3γ and -ε, commonly affected in neurodegenerative diseases.
MMP14, TIMP2, α-enolase and 14-3-3ε, indirectly involved in Aβ metabolism, as well as
Septin-2 showed changes that increase Aβ levels. Increased 14-3-3γ may contribute to
GSK3β driven tau hyperphosphorylation and CRMP2 Thr514 and Ser522 phosphorylation
with the Thr555-site, a target for Rho kinase, showing time-dependent changes. IL-18 also
increased caspase-1 levels and vacuolization of the cells. Although our SH-SY5Y cells were
not aged, as neurons in AD, our work suggests that heightened or prolonged IL-18 levels
can drive protein changes of known relevance to AD pathogenesis.
Keywords: Interleukin-18, inflammation, neurodegenerative diseases, proteomics, oxidative stress related
proteins, CRMP2, DDAH, MMP14
Abbreviations: Aβ, Amyloid-β; ACN, Acetonitrile; AD, Alzheimer’s disease;
ADMA, N(G),N(G)-dimethyl-L-arginine; APP, Amyloid-β precursor pro-
tein; ATRA, all-trans retinoic acid; BACE-1, β-site APP cleaving enzyme
1; BDNF, brain derived neurotrophic factor; BLVR, biliverdin reductase;
BR, bilirubin; BV, biliverdin; Cdk5, cyclin dependent kinase-5; CHAPS,
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulphonate; CRMP2,
collapsin response mediator protein 2; Cu/Zn-SOD, Cu/Zn-superoxide dismutase-
1; DDAH, N(G), N(G)-dimethylarginine dimethylaminohydrolase; DDAHr,
DDAH2 antibody reactive protein; 2D-DIGE, two-dimensional fluorescence dif-
ference gel electrophoresis; DJ-1, Parkinson disease protein 7; DTT, dithiothreitol;
ECM, extracellular matrix; EDTA, ethylenediaminetetraacetic acid; ENOA, enolase
α; ENOG, enolase γ; ERK, extracellular signal-regulated kinase; ESI, electrospray
ionization mass spectrometry; FA, formic acid; GSK3β, glycogen synthase kinase-
3β; HO, heme oxygenase; HPLC, High-performance liquid chromatography;
IAA, iodoacetamide; ICE, interleukin-ıβ convertin enzyme; IDO,indoleamine 2,3-
dioxygenase; IGIF, interferon-γ inducing factor; IL-18BP, interleukin-18 binding
protein; IFNγ, interferon-γ; LC-MS, liquid chromatography-mass spectrometry;
LRRK2, leucine-rich repeat serine/threonine-protein kinase 2; MALDI; matrix-
assisted laser desorption ionization; MAPK, mitogen activated protein kinase;
MMA, N(G)-monomethyl-L-arginine; MS, mass spectrometry; MScl, multiple
sclerosis; MMP14/MT1-MMP, membrane-type-1 matrix metalloproteinase; M-W;
Mann–Whitney U-test; MW, molecular weight; NFT, neurofibrillary tangles;
NOS, nitric oxide synthase; OS, oxidative stress; PAGE, polyacrylamide gel elec-
trophoresis; PBS, phosphate buffered saline; PD, Parkinson disease; pI, isoelectric
point; PI3K, phophatidylinositol 3-kinase; PKC, protein kinase C; PMF, peptide
mass fingerprint; PRX, peroxiredoxin; PS-1, presenilin 1; ROS, reactive oxygen
species; RT, room temperature; SDS, sodium dodecyl sulfate; s.e.m., standard error
of mean; Sem3A, semaphorin- 3A; SEPT2, Septin-2; TBS, tris buffered saline;
TCEP, tris (2-carboxyethyl) phosphine hydrochloride; TFA, trifluoroacetic acid;
TIMP2, tissue inhibitor of metalloproteinases 2; TLR4; toll-like receptor 4; TOF,
time of flight; tPA, tissue-type plasminogen activator; T-t, Student’s t-test; uPA,
urokinase-type plasminogen activator; WIB, western immunoblotting.
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INTRODUCTION
The most common form of dementia is sporadic, late-onset
Alzheimer’s disease (AD), the etiology of which is still unknown.
As well as contributory environmental factors and increased inci-
dence in females, well-established risk factors for sporadic AD
include aging, type-2 diabetes and obesity, which all involve
increased inflammation levels (Bendlin et al., 2010; Hamer et al.,
2012). The neuropathological hallmarks of AD include extracel-
lular neuritic amyloid-β (Aβ) plaques and intraneuronal neu-
rofibrillary tangles (NFTs) containing hyperphosphorylated tau
(Braak and Braak, 1997). In addition to neuronal loss, chronic
inflammation, oxidative stress (OS), and excitotoxic damage char-
acterize AD brains (Braak and Braak, 1991; von Bernhardi and
Eugenín, 2012; Morales et al., 2014). However, the pathologi-
cal sequelae and the interaction of these mechanisms during the
course of the disease are largely unknown.
Inflammation in the brain is primarily driven by acti-
vated microglia and astrocytes, leading to the over-production
of inflammatory cytokines and other inflammatory products
in association with increased reactive oxygen species (ROS)
(Morales et al., 2014). The interleukin-1 family member
interleukin-18 (IL-18), also known as IL-1γ or interferon-γ-
inducing factor (IGIF), is an inflammatory cytokine that is pro-
duced mainly by activated microglia in the brain. Previously we
showed that expression of this upstream cytokine is elevated in
many AD brain regions (Ojala et al., 2009). IL-18, indirectly
via interferon-γ (IFNγ) induction, can also increase indoleamine
2,3-dioxygenase (IDO), in turn producing neuroregulatory and
excitotoxic tryptophan catabolites that are proposed to con-
tribute to AD neuropathology (Guillemin et al., 2005; Anderson
and Ojala, 2010). As with IL-1β, IL-18 is cleaved by caspase-1
[interleukin-1β converting enzyme (ICE)] to an active secreted
form. In comparison to IL-1β, IL-18 expression is higher, partly
due to its longer half-life (Ojala et al., 2009), suggesting that
it may exert a more significant impact in the brain than the
more extensively researched IL-1β. The normal function of brain
IL-18 is unknown, but it may have a role in central nervous sys-
tem development as well as contributing to brain immune and
inflammatory processes (Ojala et al., 2008; Alboni et al., 2010).
Interestingly, increased IL-18 levels have also been detected in
type-2 diabetes (Aso et al., 2003), obesity (Esposito et al., 2002),
and ischemic heart disease (Mallat et al., 2001). IL-18 is also
induced during physical/emotional stress responses (Sugama and
Conti, 2008; Yaguchi et al., 2010), and is a susceptibility factor for
depression (Haastrup et al., 2012), another condition that is inti-
mately associated with neurodegenerative processes (Diniz et al.,
2013).
Here we tested time-related impacts of pro-inflammatory IL-
18 in pure human neuron-like cells. We hypothesized that IL-18
has a role in the development of neuropathological changes
related to several neurodegenerative diseases including AD. This
is based on our recent findings showing IL-18 effects on tau and
its phosphorylation (Ojala et al., 2008), as well as on amyloid
precursor protein (APP) processing and Aβ production (Sutinen
et al., 2012) in differentiated SH-SY5Y neuron-like cells. The
main aim of the present study was to discover other relevant
molecules and/or mechanisms in these human cells that are
regulated by IL-18 and that may have general importance in
the pathogenesis of neurodegenerative diseases, including AD.
We used two-dimensional difference-in-gel electrophoresis (2D-
DIGE) and mass spectrometry (MS) to find IL-18 regulated
targets. The findings were verified by western immunoblotting
(WIB).
Our study showed that IL-18 induces time-dependent effects
on protein expression profiles in differentiated neuron-like SH-
SY5Y cells. The most significant protein changes were found at
24 h but were also evident at 48 and 72 h post-IL-18 treatment,
vs. untreated control cells. Following the detection of altered pro-
teins, we focused on targets related to OS. The most interesting
targets, DDAH, Septin-2 and MMP14 were also studied from
frontal and occipital lobes of AD-patients and healthy controls,
as well as the impact of Aβ on their expression. We also evalu-
ated the vacuolization of the neuron-like SH-SY5Y cells and their
caspase-1 expression.
MATERIALS AND METHODS
CELL CULTURE AND TREATMENTS
SH-SY5Y neuroblastoma cells (DSMZ, Germany) were cultured
in Dulbeccos’s medium (BioWhittaker/Cambrex, Belgium)
containing 4.5 g/L glucose, 5% fetal bovine serum (FBS;
HyClone/Pierce; Logan, UT, USA), 2mM L-glutamine
(Cambrex/Lonza), 100 U/ml penicillin and 10μg/mL strep-
tomycin (Cambrex/Lonza) in a humidified atmosphere 5% CO2
at 37◦C. The cells were plated as 3 × 105 cells/well into the
6-well plate (Nunc™, Denmark), and differentiated within 3
days of treatment with 10μM all-trans retinoic acid (ATRA;
Sigma-Aldrich, St. Louis, MO, USA) followed by 4 days of
50 ng/mL human recombinant brain derived neurotrophic factor
(BDNF, Alomone labs, Israel) (Sutinen et al., 2012). Bioactive
recombinant human IL-18 (MBL Medical Biological laboratories
Co, Ltd., Japan) was added to the culture medium at 150 ng/mL
for 24, 48, and 72 h. BDNF was also present during the IL-18
treatments. Since the concentration of IL-18 and BDNF is not
known in the very close proximity of the release site, we used
an excess concentration (physiological 40–80 ng/ml), also due to
their recombinant origin and effort to force the time frame of
the experiment to 72 h due to the technical reasons. Also IL-18
binding protein (IL-18BPa/Fc Chimera; R&D Systems) and Aβ42
(Bachem) were used in some experiments.
After the treatment, the washed cells were lysed by using
M-PER® Mammalian Protein Extraction Reagent (Pierce). The
culture medium was also collected. The protein content was
determined with DC Protein assay (BioRad) and samples were
stored in −80◦C.
PROTEIN LABELING
Protein samples (135μg) were prepared from lysates of control
and IL-18 treated cells, then purified using the 2-D clean up-kit
(GE Healthcare) in accordance with the manufacturer’s protocol.
Samples of culture medium from the controls and IL-18 treated
(500μL) wells were concentrated to 15μL by using Nanosep 3K
omega centrifugal devices (Pall Corporation). CyDye DIGE Fluor,
minimal labeling kit (GE Healthcare) was used for labeling of the
lysate or medium proteins. Internal standards, consisting of an
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aliquot of all the samples to be used in a particular experiment,
was mixed and labeled with Cy2 dye. Control and IL-18 treated
samples were randomized and half of these samples were labeled
with Cy3 and the other half with Cy5. All dyes were incubated for
30min in the dark on ice in accordance with the manufacturer’s
protocol (GE Healthcare). Labeling was terminated by incubation
with 1μL of 10mM L-lysine for 10min on ice.
TWO-DIMENSIONAL GEL ELECTROPHORESIS (2D-DIGE)
The first dimension 4–7NL ImmobilineTMDryStrips, 24 cm (GE
Healthcare) were rehydrated over night by using DeStreakTM
rehydration solution (GEHealthcare) and IPG buffer pH 4–7 (GE
Healthcare). The labeled samples were formulated for the strips
by adding an equal volume of 2× buffer consisting of 7M urea,
2M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulphonate (CHAPS), 2% IPG buffer and 2% dithio-
threitol (DTT) (GE Healthcare), followed by incubation on ice
for 15min, after which the samples were cup-loaded into the
rehydrated strips. The first dimension was run by applying
500V (500 kVh), 1000V (5200 kVh), 8000V (16500 kVh), and
finally 8000V (42200 kVh) by using an EttanTM IPGphor unit
(Amersham). The focused strips were equilibrated in 2% sodium
dodecyl sulfate (SDS) equilibration buffer containing 6M urea,
50mM Tris pH 8.8, 30% glyserin and 0.002% bromophenol blue,
first with added 1%DTT at RT for 12min, followed by buffer sup-
plemented with 2.5% iodoacetamide (IAA) for another 12min at
room temperature (RT). After the equilibration, the strips were
loaded into the 12.5% SDS-polyacrylamide gels (1mm) in an
Ettan DALT-separation unit (Amersham) and run at 12W/gel for
30min and 128 W/gel until the bromophenol blue front reached
the bottom of the gel. Each gel run contained six separate exper-
iments from the same time-point. Since the minimal labeling
technique (Unlü et al., 1997) labels each protein with a maxi-
mum of only one dye molecule per protein (Swatton et al., 2004)
and all of the dyes have identical molecular weights (MW) and
isoelectric points (pI) but differ in their excitation and emission
wavelengths, the MW of the proteins were minimally affected.
The 2D images were visualized by Typhoon 9400Variable Mode
Imager scanner (GE Healthcare) using 488, 523, and 633 nm
lasers for Cy2, Cy3, and Cy5 dyes.
SPOT ANALYSIS
All the protein-spots in the gel images were quantified by using
the DeCyder 6.5.11 software (GE Healthcare). A DeCyder differ-
ential in-gel analysis module was used for pair wise comparisons
of each sample (Cy3 and Cy5) to the Cy2 mixed standard present
in each gel. The DeCyder biological variation analysis module was
then used to simultaneously match all the protein-spot images
from the six gels and to calculate average abundance ratios across
the samples. The protein-spots in the gels were compared to the
2D map databases (SWISS-2DPAGE and SWISS-PROT).
MASS SPECTROMETRY (MS)
Differentiated proteins within the gels were stained with
PlusOne™ Silver Staining Kit (GE Healthcare) according to
manufacturer’s instructions. The proteins of interest were cut
out manually from the silver stained gels, shrank with ace-
tonitrile (ACN) and cleaved with trypsin (Sequencing grade
Modified Trypsin V5111; Promega, Madison,WI, USA) at+37◦C
overnight. Protein MS identification was done in collabora-
tion with the protein chemistry research facility in University
of Helsinki, Viikki, and Department of Biosciences, University
of Eastern Finland, Kuopio. In the University of Helsinki, the
cleaved samples were purified with ZipTip-method and eluted
directly from the tips onto a MTP 384 ground steel sample
plate with saturated α-cyano-4-hyrdoxycinnamic acid in 0.1%
trifluoroacetic acid (TFA) and 60% ACN. Matrix-assisted laser
desorption ionization—time of flight (MALDI-TOF) mass spec-
trometer mass spectra for peptide mass fingerprints (PMF) and
MALDI-TOF/TOF mass spectra for identification by fragment
ion analysis were acquired in positive ion reflectron mode using
an Ultraflex TOF/TOF instrument (Bruker Daltonik GmbH,
Bremen, Germany). The PMF spectra were processed with
FlexAnalysis (version 3.0) and spectra were internally calibrated
by using trypsin peaks. Separation of the protein digests liquid
chromatography-MS/MS (LC-MS/MS) were done on a C18 col-
umn by using a nanoscale high-performance liquid chromatog-
raphy (HPLC) system (Ultimate 3000; Dionex, Sunnyvale, CA).
The samples were concentrated and desalted on a C18 precolumn
(PROTECOL; SGE Analytical Science, Griesheim, Germany) at
a flow rate 7μL/min (0.1% TFA). Peptides were eluted with a
linear gradient of ACN in 0.1% formic acid (FA) at a flow rate
of 200 nL/min. MS/MS of tryptic peptides was conducted on
a hybrid quadrupole/TOF mass spectrometer with NanosprayII
source (QSTAR Elite; Applied Biosystems, Foster city, CA). The
Nanospray was generated using a PicoTip needle. The peak list
was generated with ProteinPilot-software (Applied Biosystem).
At the University of Eastern Finland, the tryptic peptides were
separated using the Ultimate/Famos/Switchos capillary liquid
chromatography system (LC Packings, Amsterdam, Netherlands).
The samples were filtered on-line through PEEK encapsulated
titanium filter (VICI/ Valco, Houston, TX, USA) and trapped
onto PepMap 100 C18 pre-column (Dionex, Sunnyvale, CA,
USA) in 0.1% FA (Sigma Aldrich, Steinhelm, Germany) with
2% ACN (Sigma Aldrich) at a flow rate of 30μL/min using
an Applied Biosystems 400 Solvent Delivery System (Applied
Biosystems). After the 3min of loading and clean-up, the pre-
column was automatically switched in-line with a C18 Mass
Spec analytical column (Grace Vydac, Hesperia, CA, USA). The
peptides were eluted using a linear ACN gradient starting from
0.1% FA with 5% ACN to 30% of 0.1% FA with 95% ACN in
35min, and finally to 100% of 0.1% FA with 95% ACN. The
LC flow was connected to the mass spectrometer by a nano-
electrospray ionization MS (ESI) ion source (MDS Sciex, South
San Francisco, CA, USA) using distally coated 10μm PicoTip
emitters (New Objective, MS Wil GmbH, Switzerland). Mass
spectra were recorded in a positive mode on a QSTAR XL
hybrid quadrupole TOF instrument (Applied Biosystems), using
information-dependent acquisition for obtaining MS/MS data.
PROTEIN IDENTIFICATION
Database searches with obtained data were performed with
Mascot search engine against the SwissProt database (http://
www.matrixscience.com). The search criteria for both Mascot
searches were human-specific taxonomy, trypsin digestion with
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one missed cleavage allowed, carbamidomethyl modification of
cysteine as a fixed modification and oxidation of methionine as a
variable modification. For the PMF spectra themaximum peptide
mass tolerance was±50 ppm. For the LC-MS/MS spectra both the
maximum precursor ion mass tolerance and MS/MS fragment
ion mass tolerance were 0.2Da and peptide charge state of +2
or +3 was used.
HUMAN SAMPLES
DDAH2, SEPT2 and MMP14 were also examined from post-
mortem human brain samples (occipital and frontal lobes as pairs
from the same individual). Control samples included 3 women
and 3 men (age 83.3 years, SD ±5.7; Braak 1.17 ±0.75, obduc-
tion delay 5.7 h ± 2.5; cause of death: four cardiac problems,
one pneumonia, one pulmonary embolism). The AD patients
included 7 women and 2 men (age 83.1 years, SD ±8.1; Braak
5.22±0.67, obduction delay 5.3 h± 3.0; cause of death: five pneu-
monia, two cardiac reasons, two pulmonary embolisms). The
samples were stored at−80◦Cuntil used. The brain tissue samples
were homogenized on ice into the lysis buffer containing 10mM
Tris pH 8.0, 150mM NaCl, 1% NP-40, 1% Triton X-100, 2mM
EDTA, and Complete Protease inhibitors (Roche Diagnostics;
Mannheim, Germany) using a pellet pestle (Kontes; Vineland,
NJ, USA). Protein levels were estimated with the DC protein
assay kit (Bio-Rad Laboratories; Hercules, CA, USA) according
to manufacturer’s protocol.
The study followed the recommendations for biomedical
research involving humans (Declaration of Helsinki of TheWorld
Medical Association 1964 including the revisions and clarifi-
cations up to Tokyo 2004 and CIOMS international ethical
guidelines for biomedical research involving human subjects),
as well as the law concerning information protection. Further,
the human studies were approved by the Ethics Committee
of Kuopio University Hospital. The written informed consents
were obtained from the subjects or their representatives by the
clinicians at the Department of Neurology, Kuopio University
Hospital. Permission to obtain the post-mortem tissue was pro-
vided by the National Board of Medical Legal Affairs/National
Supervisory Authority for Welfare and Health.
WESTERN IMMUNOBLOTTING (WIB)
For WIB, equal amounts of protein (25 or 35μg) from cell lysates
or human brain samples, and equal volumes of cell culture media
(120μL) were electrophoresed in 12.5% SDS-polyacrylamide
gels. Proteins were transferred to Hybond-P PVDF membrane
(Amersham Biosciences/GE Healthcare). Full-Range and Low-
Range Rainbow Molecular Weight Markers (GE Healthcare)
as well as Spectra™ Multicolor Broad Range Protein Ladder
(Fermentas) were used for the detection of target proteins cor-
rect MW. The antibodies were commercial and evaluated by
the suppliers and end users (Table 1). However, we performed
some characterization studies for a number of antibodies that
required validation due to a partially limited use of some of
them in the literature. Those studies included different cell lines
known to express or had low expression of the targets as well
as known inducers (Supplementary data 1). A peptide inhibition
assays were also performed to determine the specificity of CRMP2
Thr555 (Supplementary data 2). The membranes were blocked
with 5% non-fat milk (Valio, Finland) in phosphate buffered
saline (PBS) containing 0.05% Tween-20 (Fluka/Sigma-Aldrich;
Steinheim, Germany) or alternatively in Tris buffered saline (TBS)
containing 0.1% Tween-20 for 1–2 h. The milk-blocked mem-
branes were immune detected for 1–2 h at RT or over night
at +4◦C with selected primary antibodies (diluted in 1:400), and
washed with PBS/0.05% Tween-20 or TBS/0.1% Tween-20 for
3 × 5min. The primary antibodies are collected in Table 1. The
antibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA), ECM Biosciences, Abcam (Cambridge,
UK), Millipore, Sigma-Aldrich and GE Healthcare. The sec-
ondary antibodies were used as 1:10000 dilution and 1.5–2 h
incubation time.
After the incubations, the membranes were washed as
described for 4 × 5min followed by 15min wash with PBS
or TBS. The targets were detected with Immobilon Western
Chemiluminescent HRP Substrate (Millipore; Billerica, MA,
USA) and documented to Fujifilm Super RX (Fuji Photo FilmCo.,
Ltd.). The x-ray films were scanned and analyzed withMCIDM5-
image analysis system (Imaging Research Inc.; Ontario, Canada).
The same membrane was used in three to four different antibody
reactions after stripping with four times wash with TBS/0.1%
Tween-20 at RT followed by shaking in stripping buffer (62.7mM
Tris pH 6.8, 2% SDS, 0.7% β-mercaptoethanol) at +50◦C for
30min and washing six times with TBS/0.1% Tween-20 at RT.
STATISTICS
The separate experiments and samples (n = 5–17) were analyzed
with parametric paired Student’s t-test (T-t) and non-parametric
Mann–Whitney U-test (M-W).
RESULTS
2D-DIGE ANALYSIS OF DIFFERENTIATED SH-SY5Y NEURON-LIKE CELLS
TREATED WITH IL-18
IL-18 altered protein profiles in SH-SY5Y cells in time related
manner
Time-dependent changes in the protein levels were apparent in
differentiated SH-SY5Y cells after 150 ng/mL IL-18 treatments
for 24, 48, or 72 h, compared to respective untreated control
cells (Table 2). The altered protein profiles with greatest dif-
ferences were identified in the cells exposed to IL-18 for 24 h,
approximately 4.2% of the total protein spots were differentially
expressed. From this total of 81 differentially expressed proteins,
27 proteins were up- and 54 down-regulated by IL-18 treat-
ment. IL-18 addition for 48 and 72 h also showed significant
protein changes vs. untreated cells (48 h: total 65; 45 increased,
20 decreased, approximately 3.3%; 72 h: total 51; 31 increased,
20 decreased, approximately 2.7%). The number of protein spots
was greatest at the 48 h time-point (1965 spots) (Figure 1A), sug-
gesting enhanced translational modifications occurring in early
expressed proteins in comparison to later proteins. Total protein
spot number was lowest in non-differentiated, untreated SH-
SY5Y neuroblastoma cells, being 1754 (Figure 1B). IL-18 also
induced some changes in the culture medium at the 72 h time-
point (Figure 1C). However, the separation of secreted proteins
from cell debris of the closed cell culture system proved difficult.
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Table 1 | The list of antibodies used in the study.
Provider Cat N:o Raised in Purification Sequence Certification for specificity
(company), user, our studies
PRIMARY ANTIBODY
PRX2 (N-13) Santa Cruz Bio. sc-23967 goat pc affinity pur. h, near the N-terminus (WB); Petrak et al., 2007; suppl.1
PRX3 (12B) Santa Cruz Bio. sc-59661 mouse mc h, full length PRX3 (WB, IF); McCommis et al., 2011;
suppl.1
PRX6 (E-18) Santa Cruz Bio. sc-55013 goat pc affinity pur. h, internal region (WB); suppl.1
DJ-1 (N-20) Santa Cruz Bio. sc-27004 goat pc affinity pur. h, near N-terminus (WB, IF); Batelli et al., 2008; suppl.1
BLVRA (2E4) Santa Cruz Bio. sc-100511 mouse mc h, recombinant BLVRA (WB); suppl.1
DDAH2 (C-19) Santa Cruz Bio. sc-26071 goat pc affinity pur. h, C-terminus (WB); Park et al., 2008; suppl.1
TIMP2 (H-140) Santa Cruz Bio. sc-5539 rabbit pc h, aa 81-220 (WB, IHC); Polyakova et al., 2008;
suppl.1
MT-MMP-1 (H-72) Santa Cruz Bio. sc-30074 rabbit pc h, aa 511-582 (WB, IHC); Saygili et al., 2011;
suppl.1
SEPT2 (N-12) Santa Cruz Bio. sc-20408 goat pc affinity pur. h, near the N-terminus (WB, IHC); Maimaitiyiming et al.,
2008; suppl.1
α Enolase (L-27) Santa Cruz Bio. sc-100812 mouse mc h, recombinant α-enolase (WB, IF, IHC); Yu et al., 2010; suppl.1
γ Enolase (N-14) Santa Cruz Bio. sc-31859 goat pc affinity pur. h, near N-terminus (WB), Yamamoto et al., 2011;
suppl.1
14-3-3-γ (C-16) Santa Cruz Bio. sc-731 rabbit pc affinity pur. h, C-terminus (WB, IF, IHC); Schindler et al., 2006;
Shiga et al., 2006; suppl.1
14-3-3-ε (E-20) Santa Cruz Bio. sc-31962 goat pc affinity pur. h, internal region (WB); suppl.1
CRMP2 (clone 1B1) Santa Cruz Bio. sc-101348 mouse mc h, synthetic peptide derived from
the C-terminus
(WB); Chi et al., 2009; suppl.1
CRMP2 (Ser522),
phospho-specific
ECM Biosci. CP2191 rabbit pc affinity pur. h, P-CRMP (S522) synthetic
peptide (coupled to carrier protein)
corresponding to aa:s surrounding
S522
(WB); Yoneda et al., 2012
CRMP2 (Thr555),
phospho-specific
ECM Biosci. CP2251 rabbit pc affinity pur. h, P-CRMP2 (T555) synthetic
peptide (couple to carrier protein)
corresponding to aa:s surrounding
T555
(WB, ICC); suppl.2
CRMP2 (Thr514) Abcam ab62478 rabbit pc affinity pur. h, synthetic phosphopeptide
derived from the phosphorylation
site of T514 (T-V-Tp-P-A)
(WB, ICC, IHC), Lim et al., 2014
Caspase 1 (14F468) Santa Cruz Bio. sc-56036 mouse mc h, aa 371-390 (WB); Zhang et al., 2012; suppl.1
Anti-Aβ[4-10]-
antibody
(W0-2)
Millipore MABN10 mouse mc protein G pur. h, amyloid β-peptide (WB, IHC); Ida et al., 1996
Anti-Alzheimer
precursor protein
A4 (22C11)
Millipore MAB348 mouse mc purified Ig pur. rc Alzheimer preucrsor A4
(pre4695) fusion protein
(WB, IHC); Mudher et al., 2001
Actin (H-196) Santa Cruz Bio. sc-7210 rabbit pc h, aa 180-375 (WB, intracell. FCM anal.); Calegari
et al., 2011
α-Tubulin (B-5-1-2,
mouse ascites
fluid)
Sigma-Aldrich T 5168 mouse mc sarkosyl resistant filaments from
sea urchin sperm axonemes
(WB, ICC); Czymai et al., 2010
SECONDARY ANTIBODY
anti-rabbit GE Healthcare NA9340 donkey affinity pur. rabbit IgG, peroxidase-linked
species specific (Fab’)2 fragment
(WB, IHC)
anti-mouse GE Healthcare NA931 sheep affinity pur. mouseit IgG, peroxidase-linked
species specific (whole antibody)
(WB, IHC)
anti-goat IgG,
(Fab’)2-HRP
Santa Cruz Bio. sc-3851 donkey affinity pur. goat IgG, conjugated with HRP (WB)
The references are listed in supplementary data.
h, human; mc, monoclonal; pc, polyclonal, suppl., supplementary data.
pur., purified; Ig, immunoglobulin; aa, amino acid; rc, recombinant; HRP, horse radish peroxidase.
WB, western immunoblot; ICC, immunocytochemistry; IF, immunofluorescence; IHC, immunohistochemistry; FCM, flow cytometry.
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Table 2 | IL-18 treatment induced protein changes in differentiated
SH-SY5Y cell lysates, including alteration in levels and modifications,
vs. to untreated control at different time-points (DeCyder spot
detection -software).
Time- Changed Up- Down- Total number
point protein spots regulated regulated of spots
24 h 81 (∼4.2%) 27 54 1934
48 h 65 (∼3.3%) 45 20 1965
72 h 51 (∼2.7%) 31 20 1866
Although the culture medium was taken gently from the cul-
tures and centrifuged prior to use, the medium likely contained
some ruptured cell contents due the delicate nature of the neu-
rites. Therefore, due to the great variation in the number of
protein spots, the medium was not possible to analyse in detail
with this number of experiment repeats (n = 6). Nevertheless,
the appearance of the IL-18 treated cells at the 72 h time-point
prior to harvest is shown in Figure 2. The 150 ng/ml IL-18 treated
cells were more vacuolized [4.1 vacuoles/ cell, standard error of
mean (s.e.m.) ± 0.17; n = 90; p ≤ 0.000 (T-t, M-W)] as well as
100 ng/ml treated cells [3.5 ±0.15; n = 90; p ≤ 0.000 (T-t, M-
W)] compared to untreated control cells (2.4 ± 0.12; n = 90).
When 150 ng ml/ IL-18 treated cells were compared to 100 ng/ml
treated ones, the increase of vacuole number was about 15.1%
[p = 0.019 (T-t); p = 0.026 (M-W)]. Cell debris was also appar-
ent indicating apoptotic cells (Figure 2).
Some of the proteins exhibiting change under 2D-DIGE were
selected (Figures 1A,C) and identified byMS. From the 79 identi-
fied proteins, 29% were involved in proliferation/ differentiation,
about 18% in cell signaling, 16% in transport and 13% in the reg-
ulation of oxidation. Proteins of interest were selected as shown
in Table 3. From these proteins, 14 were of known relevance to
neurodegenerative diseases and so were further analyzed by WIB.
WESTERN IMMUNOBLOT ANALYSES OF 2D-DIGE IDENTIFIED
PROTEINS WITH NEURODEGENERATION RELEVANCE
Oxidative stress related proteins
Due to the modest changes in expression level observed in 2D-
DIGE, the results were verified by WIB with an increased number
of repeats along with an additional 6 h time-point. Of the iden-
tified proteins, our interest focused on those involved in the
oxidative damage evident in AD brains. The WIB data have
been collated in Table 4. Protein levels of cytoplasmic peroxire-
doxin (PRX) 2 were reduced by 24.8% at the 48 h time-point,
with mainly mitochondrial PRX3 showing a pronounced 542%
increase at 6 h in IL-18 treated cells, compared to untreated
controls. Cytoplasmic vesicle-localized PRX6 (Acidic calcium-
independent phospholipase A2) was also increased by 124% at
6 h upon IL-18 treatment. The atypical peroxiredoxin-like per-
oxidase DJ-1 (Park-7), which also prevents synuclein aggregation
(Baulac et al., 2009), was reduced by 24% in 48 h treated cells.
The levels of another type of antioxidant, cytoplasmic biliverdin
reductase A (BLVRA), showed a 91% increase at the 6 h treatment
time-point. DDAH2, involved in the nitric oxide (NO) pathway as
well as in apoptosis regulation (Wang et al., 2009), was increased
FIGURE 1 | An example sets of 2D-DIGE protein profiles of SH-SY5Y
cells. (A) Differentiated SH-SY5Y cells, at the 48 h time-point where the
number of protein spots was the greatest. The arrow heads indicate the
picked proteins, done from the silver stained gels; protein ID: (1) PRX2, (2)
PRX3, (3) PRX6, (4) DJ-1, (5) BLVRA, (6) DDAH1, (7) DDAH2, (8) TIMP2, (9)
SEPT2, (10) ENOA, (11) ENOG, (12) 14-3-3γ, (13) 14-3-3ε, (14) RUFY3, (15)
CRMP2. (B) Undifferentiated SH-SY5Y neuroblastoma cells showed the
least number of spots, in comparison to differentiated SH-SY5Y cells in (A).
(C) Protein profile of the culture medium of the differentiated SH-SY5Y cells
at the 72 h time-point. Protein ID 8, TIMP2, was picked from the medium
gel. The strip pI range was the same in all shown gels.
by 40% at 48 h in IL-18 treated cells vs. untreated controls. IL-
18 showed a concentration dependent DDAH2 increase at 72 h
(Figure 3A). DDAH1 also showed an increase at the 72 h time-
point in the 2D-DIGE analyses, but its expression was not further
analyzed by WIB.
A concentration of 150 ng/ml of IL-18 was used in these exper-
iments given our previous work showing that IL-18 does not
seem to trigger apoptosis at a concentration of 100 ng/ml (Ojala
et al., 2008). This may be due to increased antioxidative pro-
tective enzymes as well as the anti-apoptotic Bcl-xL, which we
have shown previously to be increased by IL-18 (Sutinen et al.,
2012). Also the presence of BDNF during these experiments will
have protective effects, given our preliminary test showing that
the removal of BDNF led to cells detaching from the culture
wells as well as increasing vulnerability to cell death. Here we
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FIGURE 2 | The appearance of the differentiated SH-SY5Y cells treated with 100 or 150ng/ml of IL-18 for 72h. The number of vacuoles (>) was higher in
150 ng/ml treated cells (about 4.1/ cell) than in untreated control (2.4/ cell) or 100 ng/ml treated cells (3.5/ cell). Some cell debris is also apparent (>>).
Table 3 | Proteins of human SH-SY5Y cells, identified with mass spectrometry and studied further with western immunoblots.
Id no Protein name Gene name SwissProt ID type No. of Sequence Mowse MW pI
peptides coverage (%) score
1 Peroxiredoxin-2 PRDX2_HUMAN P32119 ESI 4 19 87 21892 5.67
2 Thioredoxin-dependent
peroxidase reductase
PRDX3_HUMAN P30048 MALDI 7 44 57 27693 5.77
3 Peroxiredoxin-6 PRDX6_HUMAN P30041 MALDI 23 83 272 25035 6.00
4 Protein DJ-1 (Park 7) PARK7_HUMAN Q99497 ESI 7 38 149 19891 6.32
5 Biliverdin reductase A BIEA_HUMAN P53004 MALDI 14 41 159 33428 6.06
6 N(G), N(G)-dimethylarginine
dimethylaminohydrolase
DDAH1_HUMAN O94760 MALDI 30 66 235 31122 5.53
7 N(G), N(G)-dimethylarginine
dimethylaminohydrolase 2
DDAH2_HUMAN O95865 MALDI 7 39 96 29644 5.66
8 Metalloproteinase inhibitor 2 TIMP2_HUMAN P16035 ESI 1 6 40 24399 6.48
9 Septin-2 SEPT2_HUMAN Q15019 MALDI 15 49 145 41487 6.15
10 Alpha-enolase ENOA_HUMAN P06733 MALDI 22 56 154 47169 7.01
11 Gamma-enolase ENOG_HUMAN P09104 MALDI 15 49 177 47269 4.91
12 14-3-3 protein gamma 1433G_HUMAN P61981 ESI 4 17 36 28303 4.80
13 14-3-3 protein epsilon 1433E_HUMAN P62258 ESI 16 45 345 29174 4.63
14 Protein RUFY3 (single
axon-regulated protein)
RUFY3_HUMAN Q7L099 ESI 11 22 57 52965 5.36
15 Dihydropyrimidinase-related
protein 2 (CRMP2)
DPYL2_HUMAN Q16555 MALDI 13 25 132 58163 5.77
used caspase-1 as a marker for apoptosis initiation showing that
IL-18 increased caspase-1 in a concentration dependent manner
(Figure 3A). Increased caspase-1 expression was also detectable
in samples from our previous study (Sutinen et al., 2012), where
the cells were treated with 1μM Aβ42 with or without 100 ng/ml
IL-18 or with IL-18 alone (Figure 4A). IL-18 as 100 ng/ml for 72 h
increased caspase-1 protein expression by 34.9% [s.e.m. ±10.9;
n = 5; p = 0.005 (M-W)] and together with 1μMAβ42 by 44.5%
(±22.2; n = 5; p = 0.095), whereas 1μMAβ42 as such by 23.3%
(±22.9; n = 5; p = 0.095).
Amyloid-β related proteins
We found changes in Aβ metabolism and its aggregation affect-
ing targets. APP levels showed an IL-18 concentration depended
reduction in 72 h treated cells (Figure 3A). IL-18 as 150 ng/ml
for 72 h reduced protein levels of APP [mean -47.5%; s.e.m.
±9.7; n = 5; p = 0.005 (M-W)]. Further, as shown previously
in a separate experiment (Sutinen et al., 2012), IL-18 treatment
induced expression of Aβ and this effect was blocked by IL-18BP
in 72 h treated cells (Figure 4C). Also Septin-2 (SEPT2), capable
of interacting with Aβ aggregates (Pissuti Damalio et al., 2012),
decreased by 28% at 24 h following IL-18 treatment but increased
to 90.0% after 72 h of treatment. The increase at 72 h was con-
centration dependent (Figure 3A). Aβ42 at 1μM(4.5 kD) with or
without 100 ng/ml IL-18 increased the higherMW form of SEPT2
(approximately 46 kD), compared to untreated control (41 kD)
(Figure 4A), suggesting interactions of Aβ with SEPT2.
Increased tissue inhibitor of metalloproteinase-2 (TIMP2) lev-
els are evident in AD and, through the inhibition of MMPs, can
regulate Aβ degradation (Liao and Van Nostrand, 2010; Merlo
and Sortino, 2012). In our studies TIMP2 increased by 77% at the
24 h time-point and by 70% at 48 h in IL-18 treated cells. A slight
increase in TIMP2 was also detectable in the culture medium after
48 or 72 h following IL-18 treatment (Figure 3D). Although not
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detected in 2D-DIGE we examined membrane type 1 metallo-
proteinase (MT1-MMP/MMP-14), which is a target for TIMP2
and can activate MMP2, possibly important in Aβ degradation
(Merlo and Sortino, 2012). Protein levels of MMP14 increased by
29% following 6 h of IL-18 and by 89% in the 72 h treated cells,
showing an IL-18 concentration dependent effect (Figure 3A).
However, whereas IL-18 slightly increased the soluble form of
MMP14 in the culture medium, 1μM Aβ42 treatment for 72 h
reduced MMP14 levels (Figure 4B).
Other neurodegenerative diseases related proteins
The other interesting targets identified included enolase and 14-
3-3 proteins, known to be altered in AD (Fountoulakis et al.,
1999; Butterfield and Bader Lange, 2009). Carbon-oxygen lyase
α-enolase (ENOA), involved in glucose metabolism, declined by
26% over 72 h of IL-18 treatment of the cells whereas γ-enolase
(ENOG), a neurotrophic-like factor promoting growth, differ-
entiation, survival and regeneration of neurons (Hafner et al.,
2012), increased by 46% following 24 h of treatment, compared
to controls. 14-3-3ε, involved in brain development and neuronal
migration (Toyo-oka et al., 2003), increased by 43% in 24 h IL-18
treated cells, whereas the 14-3-3γ isoform, which displays similar
functions, increased by 112%, but only at 6 h of IL-18 treatment.
Increased expression of RUFY3 (single axon-regulated pro-
tein) (Mori et al., 2007) was also detected after 72 h in IL-18
treated cells under 2D-DIGE, but this finding was not veri-
fied by WIB. Collapsin response mediator protein 2 (CRMP2;
Dihydropyrimidinase-related protein 2) was examined given
its variety of roles in neurons including development, polar-
ity and neuron projection morphogenesis, axon growth and
guidance, neuronal growth cone collapse, and cell migration
(Higurashi et al., 2012). We found CRMP2 (62.3 kD, isoform 1;
58.2 kD isoform 2) to be modified at least at its Ser522, Thr514,
and Thr555 sites (Figures 3A,B). Also, a higher MW-form of
CRMP2, induced by 150 ng/ml IL-18 treatment, was detectable
(Figure 3C). CRMP2 is modified by phosphorylation of several
sites, and possibly also in other ways.
Protein levels of DDAH2, SEPT2, and MMP14 were altered in the AD
brain
Based on the above, the most interesting targets were exam-
ined from frontal and occipital lobe post-mortem samples of AD
patients and healthy age matched controls. An example set of
DDAH, SEPT2 andMMP14 is shown in Figure 5, and it describes
general changes in occipital and frontal lobe samples from one
control and one AD patient, examined from the sameWIB mem-
brane. As collected in Table 5, we found that in occipital lobe,
DDAH2 (approximately 29 kD) and SEPT2 levels reduced about
77% in AD patients, whereas DDAH2 antibody reactive protein
(DDAHr; approximately 55 kD) increased in frontal lobe almost
140% compared to healthy controls. In healthy controls, DDAHr
(approximately 55 kD) was about 50% less in frontal lobe than in
occipital lobe. This 55 kD DDAHr form requires further studies.
In AD patients, MMP14 was increased around 80% compared to
healthy controls, although its general level in AD patients seemed
to be less than in healthy controls in both lobes. Therefore,
the general slight reduction of MMP14 levels in AD may alter
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FIGURE 3 | Western immunoblot verification of the selected targets.
(A) IL-18 induced our apoptosis marker caspase-1 in a concentration
dependent manner, with APP level reduced in 72 h treated cells. DDAH2
and SEPT2 levels are increased as well as processed MMP14 (54 kD)
and precursor MMP14 (above, 66 kD, propeptide 64 kD). The 30 kD form
may be some a non-typical cleavage form of MMP14 (antibody detects
aa 511–582 at C-terminus). CRMP2 P-Ser522 specific antibody detected a
faint concentration dependent band (>). CRMP2 P-Thr514 also increase
(>), with the intensity of CRMP2 different to that of CRMP-2 P-Ser522.
Also an additional band about 30 kD was detectable. All the results are
from the same membrane. (B) CRMP2 also showed increased
phosphorylation at Thr555 at 24 and 48 h time-points, after which it
reduced, as detected by specific antibody. The band about 30 kD, was
evident only at 24 h. Tubulin shows some co-regulation. Non-specific band
indicates evenness of sample loading. (C) CRMP2 was studied also with
non-phosphor specific antibody after 150 ng/ml IL-18 treatment. CRMP2
(isoform 1: 62 kD, isoform 2: 58 kD) were unaffected, but high MW-form
above was IL-18 responsive (>), which may be a modified form of
CRMP2. CRMP is phosphorylatable at several sites but other
modifications may also exist. Actin was used as a loading control. (D)
IL-18 at 150 ng/ml also increased TIMP2 levels in the culture medium of
SH-SY5Y cells vs. untreated control.
for instance the Aβ degradation pathways. The specific role of
MMP14 in ADpathogenesis requires further investigation. Due to
the biological variations of human samples, more definite results
of the given targets require higher number of AD and control
samples.
In conclusion, the results of many neuronal cell types includ-
ing post mortem AD samples do not correlate well in our living
one cell type neuronal model in this number of repeats. However,
our model may describe the events in neurons in vivo when acute
high levels or even chronic lower levels of IL-18 are present.
Our earlier concentration studies have suggested that lower doses
of IL-18 (50 ng/ml) also have similar effects than higher 100 or
150 ng/ml doses, but in a longer timeframe, apparent also in some
level in Figures 3A,B. For the maintenance of the cells, longer
than 72 h incubation time would require the culture medium
change leading to distortions of the experiment as well as the
results.
DISCUSSION
In the present study, we found that IL-18 had time-dependent
effects on protein expression profiles in differentiated neuron-like
SH-SY5Y cells. As summarized in Figure 6, our study shows that
IL-18 either by itself or through induction of OS, differentially
induces protective enzymes, as well as proteins associated with Aβ
degradation vs. accumulation and apoptosis. IL-18 was shown to
regulate targets affecting glucose metabolism, survival and regen-
eration, neuronal differentiation, and brain development. Many
of these proteins have previously been studied in different AD
brain regions, and are linked to AD/dementia (Korolainen et al.,
2010). The findings are also in line with our earlier studies show-
ing increased IL-18 in the brain of AD patients (Ojala et al., 2009),
in turn contributing to many time-dependent protein changes,
which can contribute to the pathogenesis of AD, including via
NFT and Aβ-plaque formation (Ojala et al., 2008; Sutinen et al.,
2012).
OS plays an important role in the pathogenesis of numerous
age-related neurodegenerative diseases including multiple scle-
rosis (MScl) and Parkinson’s disease (PD) (Anderson and Maes,
2014), as well as AD, by inducing cell damage and wider inflam-
matory processes (Krapfenbauer et al., 2003). Uncontrolled OS
can lead to apoptosis but it can also cause sublethal damages
that induce regenerative mechanisms (Ojala et al., 2008), lead-
ing to protein alterations typical of AD. However, Aβ itself can
also induce OS (Opazo et al., 2002) and, as we showed, IL-
18 can induce Aβ-production. Oxidatively modified proteins in
turn are associated with tau and Aβ pathology (von Bernhardi
and Eugenín, 2012). The brain is highly sensitive to OS due to
its richness of fatty acids that can undergo peroxidation and its
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FIGURE 4 | Differentiated SH-SY5Y cells treated with IL-18 and/or Aβ42
and blocked with IL-18BP. (A) Treatment with IL-18 (100 ng/ml) or 1μM
Aβ42 increased caspase-1 expression, especially synergistically at 72 h.
SEPT2 analysis showed an extra band above the 41 kD main band, which is
particularly strong in Aβ42 treated cells and IL-18 + Aβ42 treated cells,
compared to untreated control. Although the results of DDAH2 are faint,
they indicate increased DDAH2 in IL-18 treated cells whereas treatment
with IL-18 + Aβ42, and particularly Aβ42, seemed to reduce its levels vs.
control. Tubulin was a loading control. The results are from the same
membrane. The appearance of these cells is shown in our previous paper
(Sutinen et al., 2012). (B) 1μM Aβ42 decreased soluble MMP14 levels in
the SH-SY5Y culture medium. (C) IL-18 at 100 ng/ml treatment for 72 h also
increased APP processing to C99 and Aβ, which was blocked by 0.5μg/ml
IL-18BP. Actin was used as a loading control.
high oxygen demand, coupled to a relative scarcity of robust
antioxidant systems (Lee et al., 2010). Among the multiple mech-
anisms and triggers by which OS can accumulate, inflammatory
cytokines can sustain oxidative and nitrosative stress, leading
eventually to increased levels of oxidation-altered metabolites.
As such, understanding of the consequences of inflammation
and OS is important since it may elucidate the initial events
underlying AD.
We found expression changes in PRXs after the IL-18 treat-
ments. PRXs (PRX1-6) are a family of multifunctional antiox-
idant thioredoxin-dependent peroxidases that are differentially
localized intracellularly, with further variation across differ-
ent cell types (Hanschmann et al., 2013). The major func-
tions of PRXs involve cellular protection against OS, including
ROS-mediated DNA-fragmentation, modulation of intracellular
signaling cascades that utilize hydrogen peroxide as a second
FIGURE 5 | Western immunoblot example set of AD and control brain
post-mortem samples. DDAH, SEPT2, and MMP14 were examined from
the age matched samples. The shown sample sets are from one control
and one AD subjects, the shown bands being detected from the same
membrane after stripping. DDAH2 reduced in oc lobe of AD patients but
increased in fr lobe, similarly as the around 40 kD form. The around 55 kD
form is possibly complexed DDAH2 (29 kD) or DDAH1 (the size of a
biological form of DDAH1 is 37 kD), as shown in 2D-gel (Figure 1, spot 6).
SEPT2 increased and MMP14 reduced in fr lobe in AD. With tubulin
antibody detected non-specific (ns) band was a loading control due to
excess intensity of tubulin. Ctrl, control; AD, Alzheimer’s disease; oc,
occipital lobe sample, fr, frontal lobe sample.
messenger molecule and the regulation of cell proliferation. PRX2
is expressed exclusively in neurons (Krapfenbauer et al., 2003).
PRX3 levels are decreased in the AD brain, and since mitochon-
dria are generally also extensively damaged in AD, leakage may
contribute to its reduction (Krapfenbauer et al., 2003). PRX6 is
increased in astrocytes, diffuse plaques and in neuritic plaques,
but not in AD neurons (Power et al., 2008). It can reduce hydro-
gen peroxide as well as short chain organic, fatty acids and
phospholipid hydroperoxides, indicating its importance in the
regulation of phospholipid turnover (Fisher, 2011). PRX2 defi-
cient neurons are particularly sensitive to hydrogen peroxide
induced cell death. PRX2, like anti-apoptotic Bcl-2 and Bcl-xL
proteins, can also interact with presenilin-1 (PS-1), thereby being
involved in processing of APP to Aβ. This binding can provide
protection against neuronal apoptosis (Alberici et al., 1999; Zhou
et al., 2002).
DJ-1 reduced by IL-18 treatment. DJ-1, a susceptibility gene
in PD, can scavenge hydrogen peroxide and function as a redox-
sensitive chaperone (Batelli et al., 2008; Baulac et al., 2009). It
can also regulate oxidant status via the modulation of Cu/Zn-
superoxide dismutase-1 (Cu/Zn-SOD) levels (Wang et al., 2011),
as well as preventing α-synuclein aggregation (Batelli et al., 2008).
DJ-1 is also detectable in tau inclusions (Rizzu et al., 2004) and
further, it is required to correct mitochondrial morphology and
function, as well as the autophagy of dysfunctional mitochondria.
Therefore, loss of its function generally leads to neurodegenera-
tion, likely mediated by mitochondria (Irrcher et al., 2010). As
a summary, the decrease in DJ-1, induced by IL-18, is likely to
have wide ranging effects, including mitochondrial function and
antioxidant regulation.
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Table 5 | Expression level changes of the selected target proteins in occipital and frontal lobes of AD patients and healthy controls.
Mean ± s.e.m. n Mean ± s.e.m. n Mean % p, T-t p, M-W Mean % p, T-t p, M-W
Ctrl, oc AD, oc AD/Ctrl, oc Ctrl, fr/oc
DDAHr ∼55 kD 1.60 ± 0.40 6 1.39 ± 0.28 9 −12.7 0.673 0.749 −49.0 0.049 0.109
DDAH2 ∼29 kD 5.44 ± 2.23 4 1.22 ± 0.65 5 −77.6 0.084 0.050 −78.9 0.055 0.083
SEPT2 4.57 ± 1.92 4 1.03 ± 0.43 5 −77.5 0.084 0.027 −56.3 0.145 0.248
MMP14 1.54 ± 0.62 6 0.94 ± 0.12 9 −38.8 0.272 0.631 48.8 0.168 0.200
Ctrl, fr AD, fr AD/Ctrl, fr AD, fr/oc
DDAHr ∼55 kD 0.82 ± 0.15 6 1.95 ± 0.32 9 138.9 0.018 0.010 39.6 0.107 0.145
DDAH2 ∼29 kD 1.15 ± 0.52 4 1.01 ± 0.40 5 −11.9 0.837 1.000 −17.3 0.394 0.917
SEPT2 1.99 ± 1.10 4 1.26 ± 0.50 5 −37.1 0.531 0.806 21.8 0.371 0.754
MMP14 2.29 ± 0.40 6 1.71 ± 0.36 9 −25.3 0.309 0.262 81.6 0.029 0.019
Mean: calculated from the numerical band densities [Graph density × area (G/DxA), expressed as a percentage of the total area scanned] after normalization with
tubulin; numerical value describes the relative intensity of the examined band.
Mean %: AD/Ctrl or frontal/occipital x100-100.
s.e.m., standard error of mean; n, number of individuals.
P, p-value [T-test, T-t (paired); Mann–Whitney U-test, M-W]; significant p-values marked as bold (0.05, 0.01, 0.001).
Ctrl, healthy control; AD, Alzheimer’s disease; oc, occipital lobe; fr, frontal lobe.
IL-18 treatment increased BLVRA levels, as evident also in
AD (Barone et al., 2011). Evolutionarily conserved BLVR and
heme oxygenase (HO) have an essential role in the fight against
OS. BLVR is expressed in all tissues as BLVRA (dominant in
adults) and BLVRB (dominant in fetal state) (Kim and Park,
2012). Multifunctional BLVR is regulated by a number of fac-
tors including biliverdin and phosphorylation, which in turn
are regulated by OS and free radicals (Wegiel and Otterbein,
2012). HO is needed to cleave the heme ring to form biliverdin
(BV), with soluble BLVR converting BV to the potent antiox-
idant bilirubin (BR) (Jansen et al., 2010). Both BR and BV
are potent scavengers of peroxyl radicals (Jansen and Daiber,
2012). BR can also interact with and neutralize NO radicals
leading to the formation of NO-bilirubin (Barone et al., 2009),
whereas BV, through NO-dependent nuclear translocation of
BLVR, inhibits Toll-like receptor-4 (TLR4) expression (Wegiel
et al., 2011), another factor known to regulate AD susceptibility
(Chen et al., 2012). Interestingly, due to the lipophilic nature of
BR, it has suggested to be particularly effective against lipophilic
ROS (Jansen and Daiber, 2012). BLVR is also known to function
as a Ser/Thr/Tyr-kinase and transcription factor as well as in cell-
signaling, mediated by protein kinase C (PKC), mitogen activated
protein kinase (MAPK), and phophatidylinositol 3-kinase (PI3K)
(Lerner-Marmarosh et al., 2005; Gibbs et al., 2012; Kim and
Park, 2012). Therefore, the increase in BLVR by IL-18 is likely to
modulate neuronal antioxidants, transcription and intracellular
signaling pathways.
Protein levels of DDAH were increased in IL-18 treated cells as
well as the higher MW DDAHr within the frontal lobes of AD
patients. DDAH controls cellular methylarginine concentration
by hydrolyzing N(G),N(G)-dimethyl-L-arginine (ADMA), and
N(G)-monomethyl-L-arginine (MMA) which act as inhibitors
for nitric oxide synthase (NOS) (Selley, 2004; Pope et al., 2009).
Catabolization of these endogenous inhibitors by DDAH may
increase NOS activity andNOproduction with resultant increases
in nitrosative stress. NO also has an important role in synap-
tic events regulating learning and memory, and its dysregulation
may lead to synaptic dysfunction (Selley, 2004). Further, NO is
a vasodilator and can regulate blood pressure (Dayoub et al.,
2008). DDAH1 localizes uniformly in the cytosol and nucleus,
whereas DDAH2 is in the cytosol (Birdsey et al., 2000), but may
also translocate tomitochondria upon IL-1β stimulation (Cillero-
Pastor et al., 2012). Interestingly, ADMA/DDAH pathway can
regulate angiogenesis (Fiedler et al., 2009). Overall, the increase
observed in DDAH1 detected in 2D-gels and DDAH2 (29 kD) fol-
lowing IL-18 treatment will alter NOS, NO, and nitrosative stress,
as well as NO related signaling processes. DDAHr (around 55 kD)
requires further studies.
TIMP2 and MMP14 levels were time-dependently increased
in IL-18 treated cells. TIMP2 inactivates matrix MMPs by
covering their catalytic zinc cofactor site (Brew and Nagase,
2010). On the other hand, MMP14 is a physiological activator
for several MMPs, including for pro-MMP2, complexed with
TIMP2 (Lehti et al., 1998; Itoh et al., 2001). MMPs can also be
activated by the free radical peroxynitrite (ONOO-) (Ridnour
et al., 2012). IL-18 inducible MMP2 and MMP9 are expressed
in SH-SY5Y cells (Ishida et al., 2004; Chandrasekar et al., 2006;
Merlo and Sortino, 2012), and further, MMP2, -9 as well as
a soluble MMP14 form can participate in the degradation of
Aβ (Liao and Van Nostrand, 2010; Merlo and Sortino, 2012).
However, increased PRX6 expression is associated with increased
levels of MMP9 and the urokinase-type plasminogen activator
(uPA) as well as decreased TIMP2 (Chang et al., 2007; Lee et al.,
2009b). Both uPA and tissue-type plasminogen activator (tPA)
are also expressed in SH-SY5Y cells (Neuman et al., 1989), and
both of them, via plasminogen, increase the protease plasmin,
also able to degrade Aβ (Tucker et al., 2000) and regulate MMP
levels. Active plasmin can also remodel the extracellular matrix
(ECM) directly, as well as indirectly via the activation of MMPs
(Baramova et al., 1997). In AD patients, MMP14 levels are higher
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FIGURE 6 | Summary figure of the WIB results. IL-18 may induce OS
due to increase of antioxidative PRX3, -6, and BLVRA in SH-SY5Y cells.
14-3-3γ (modulator of apoptosis; intracellular trafficking; cell cycle control;
signal transduction; and metabolism), 14-3-3ε (anti-apoptotic; a component
of the prion/amyloid deposits of Gerstmann-Straüssler-Scheinker disease).
14-3-3ε can bind PRX6, translocating PRX6 to lysosomes when MAPK is
activated. Both 14-3-3γ and -ε can prevent α-synuclein inclusion formation.
14-3-3 proteins can complex with tau and GSK3β promoting tau
phosphorylation and NFT formation. 14-3-3ε can increase MMP2. TIMP2
(MMP inactivator), MMP14 (a physiological activator for pro-MMP2
complexed with TIMP2). IL-18 inducible MMP2 and MMP9 are also
expressed in SH-SY5Y cells. MMP2, -9 and soluble MMP14 can participate
in Aβ degradation. Increased PRX6 is linked with increased MMP9 and
uPA, and decreased TIMP2 expression. uPA and tPA are expressed in
SH-SY5Y cells, and both, via plasminogen, increase protease plasmin, also
able degrading Aβ and regulating MMP levels. Active plasmin can remodel
directly and indirectly, via activation of MMPs, the ECM. ENOG
(glycolysis; a neurotrophic-like factor promoting growth, differentiation,
survival, and regeneration of neurons). The neurotrophic activity is
mediated by the C-terminus which activates PI3K/Akt and MAPK/ERK.
Cathepsin X, which activity increases during aging and interacts also with
Aβ-plaques, cleaves the C-terminus of ENOG and ENOA, impairing the
survival and neuritogenesis of neuronal cells. DJ-1 (scavenges H2O2;
modulates Cu/Zn-SOD; a redox-sensitive chaperone; prevents α-SNC
aggregation; detectable in tau inclusions; loss of function leads to
neurodegeneration, likely mediated by mitochondria). DDAH (regulates
apoptosis; controls cellular methylarginine concentration by hydrolyzing
NOS inhibitors ADMA and MMA). DDAH can increase NOS activity, NO
production and resultant increase in nitrosative stress. NO also regulates
learning and memory. ONOO- can activate MMPs. ENOA (glycolysis;
plasminogen receptor). Interaction of plasminogen with ENOA enhances
its activation to plasmin by tPA or uPA. Modifications of ENOA can lead to
its catalytic inactivation, which can alter its role as a plasminogen
receptor, effecting ECM remodeling, neuronal survival and Aβ degradation.
SEPT2 (interacts with Aβ; linked to pathological features of Aβ plaques
and NFTs; filament-forming cytoskeletal GTPase that can modulate
cytokinesis, cell division, exocytosis, and membrane trafficking). Generally,
Septins form hetero-oligomeric complexes which assemble into filaments,
mediated by the GTPase activity. CRMP2 (mediates Sem3A signaling in
the nervous system; interacts e.g., with tubulin, Numb, kinesin1, and
Sra1; promotes axon elongation; phosphorylated by several Ser/Thr
kinases (ROCK: Thr555, Cdk5: Ser522, GSK3β: Ser518, Thr514,509).
Ser522-phosphorylation is essential for sequential phophorylations by
GSK3β at Ser518 and Thr514,509. These phosphorylation steps are
required in Sem3A signaling. The phosphorylations disrupt the interaction
of CRMP2 with tubulin or Numb. CRMP2 hyperphosphorylation is an early
event in AD progression and occurs downstream of APP, but neither
excessive Aβ42 peptide nor neurotoxicity alone are sufficient to promote
it. CRMP2 hyperphosphorylated at Thr509 and Ser518,522 is also present
in NFTs. IL-18 can induce Cdk5 and GSK3β and caspase-3 (Ojala et al.,
2008) as well as APP, BACE-1, and PS-1 (Sutinen et al., 2012) marked as
smaller font. Interactions are shown with dashed lines.
in the frontal lobe compared to the occipital lobe, but seemed
to be less than in healthy controls. As such, IL-18 regulation of
PRX6, TIMP2, NO, MMPs and MMP14 may be associated with
the regulation of Aβ production as well as plasmin and MMP
mediated Aβ degradation.
Whereas ENOG levels increased, ENOA levels declined time-
dependently in IL-18 treated cells. Homo- or heterodimeric ENOs
are glycolytic enzymes, which are also associated with hypoxia
and ischemia as well as AD (Sultana et al., 2007; Butterfield
and Bader Lange, 2009). ENOA is consistently found to be
up-regulated in mild cognitive impairment and AD, in which
glucose hypometabolism and upregulation of glycolytic enzymes
are predominant features (Castegna et al., 2002). ENOA can
be glycosylated (Owen et al., 2009), oxidized (Castegna et al.,
2002), glutathionylated (Newman et al., 2007), or nitrated (Reed
et al., 2009), which, when elevated, lead to its catalytic inactiva-
tion. Depending on the pathophysiological condition of the cells,
ENOA can also function as a plasminogen receptor on the sur-
face of several cell types (Díaz-Ramos et al., 2012). Interaction
of plasminogen with ENOA enhances its activation to plasmin
by tPA or uPA (Sinniger et al., 1999). However, ENOA modi-
fications that lead to its catalytic inactivation are also likely to
alter its role as a plasminogen receptor (Gentile et al., 2009),
with consequences for ECM remodeling, neuronal survival and
Aβ degradation. Although ENOG levels are increased markedly,
for instance in cardiovascular disease, cerebral trauma, brain
tumors, and Creutzfeldt-Jakob disease, it can also function as a
neurotrophic-like factor promoting growth, differentiation, sur-
vival, and regeneration of neurons after translocation and binding
to the plasmamembrane (Aksamit et al., 2001; Hafner et al., 2010,
2012). Its neurotrophic activity is regulated by the C-terminal
peptide which activates the PI3K/Akt and MAPK/ERK signaling
pathways (Hafner et al., 2012). Cathepsin X, the activation of
which increases in an age-dependent manner and is also associ-
ated with Aβ-plaques (Wendt et al., 2007), cleaves the C-terminal
amino acids of ENOG as well as ENOA, impairing the survival
and neuritogenesis of neuronal cells (Obermajer et al., 2009).
Whether cathepsin X is inducible by IL-18 is unknown.
We found time-dependent changes in the expression of 14-3-3
proteins. Generally, the 14-3-3 family of proteins is a highly con-
served group of molecules that play important roles in apoptosis,
intracellular trafficking, cell cycle control, signal transduction,
and metabolism (Steinacker et al., 2011). 14-3-3ε can protect
against ischemic cerebral infarction and neuronal apoptosis (Wu
et al., 2009), but it is also a component of the prion protein amy-
loid deposits of Gerstmann-Straüssler-Scheinker disease (Di Fede
et al., 2007) indicating a role in amyloid regulation in other neu-
rological conditions. 14-3-3ε can also bind PRX6, which leads to
translocation of PRX6 to lysosomal organelles in the presence
of MAPK activity (Sorokina et al., 2011). 14-3-3γ and 14-3-3ε
also have binary interactions with leucine-rich repeat Ser/Thr-
protein kinase 2 (LRRK2), detected in α-synuclein positive Lewy
bodies, as well as in Hirano bodies in AD (Perry et al., 2008;
Li et al., 2011). Both 14-3-3γ and -ε can prevent α-synuclein
inclusion formation (Yacoubian et al., 2010) and via its associa-
tion with phosphorylated Bad prevent its apoptotic actions (Koh,
2008). 14-3-3 proteins can also bind simultaneously to tau and
GSK3β and promote tau phosphorylation and formation of NFTs
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(Yuan et al., 2004). Further, 14-3-3ε can increase MMP2 expres-
sion via p38 MAPK signaling (Lee et al., 2009a). As such, the
different 14-3-3 isoforms have variable effects that may contribute
to AD degenerative processes, as well as having wider beneficial
effects, which will be modulated by IL-18.
IL-18 regulated SEPT2 expression in time-dependent manner.
There was also an indication that SEPT2 levels are increased in the
frontal lobe compared to occipital lobe of AD patients, although
this requires further investigation. SEPT2, capable of interacting
with Aβ aggregates, has been linked with NFTs and pathologi-
cal features of Aβ plaques in AD (Kinoshita et al., 1998; Pissuti
Damalio et al., 2012). SEPT2 is a member of the septin fam-
ily, which is a conserved group of filament-forming cytoskeletal
GTPases. The members form hetero-oligomeric complexes which
assemble into filaments in a GTPase activity required manner. As
such the septins have a wide range of physiological effects, includ-
ing roles in the regulation of cytokinesis, cell division, exocytosis,
and membrane trafficking (Peterson and Petty, 2010; Mostowy
and Cossart, 2012).
The other interesting targets, found in 2D-DIGE, were RUFY3
and CRMP2. RUFY3 is implicated in single axon formation by
developing neurons due to its ability to inhibit PI3K in minor
neuronal processes, thereby preventing the formation of addi-
tional axons (Mori et al., 2007). We also found time-dependent
changes in phosphorylation of CRMP2. CRMP2 is a member of
the CRMP family and promotes axon elongation in primary hip-
pocampal neurons or SH-SY5Y cells (Cole et al., 2004). CRMP2
seems to be involved in neurodegenerative mechanisms common
to AD and quite possibly also other neuroinflammatory condi-
tions, such asMScl (Petratos et al., 2008, 2012). Generally, CRMPs
are the major phosphoproteins in the developing brain, and they
mediate Semaphorin3A (Sem3A) signaling in the nervous sys-
tem. They interact with many factors, including tubulin, Numb,
kinesin1, and Sra1 (Uchida et al., 2009). For instance CRMP2 is
phosphorylated by several Ser/Thr kinases, such as Rho kinase
(ROCK), Cdk5, and GSK3β especially at its C-terminal sites. As
we showed previously, IL-18 can induce Cdk5 and GSK3β (Ojala
et al., 2008), suggesting a role for IL-18 in the regulation of
CRMP2. ROCK phosphorylates CRMP2 at Thr555 and Cdk5 at
Ser522, with Ser522-phosphorylation being essential for sequen-
tial phophorylations by GSK3β at Ser518, Thr514, and Thr509.
This sequential phosphorylation of CRMP2 by Cdk5 and GSK3β
is a necessary step in Sem3A signaling (Uchida et al., 2009),
with the CRMP2 phosphorylations disrupting the interaction
with other factors including tubulin or Numb. Further, Sem3A
or ROCK pathways seem to independently regulate growth cone
collapse (Arimura et al., 2000), whereas phosphorylation sites
and levels of CRMP2 may control axon growth by coordinat-
ing the stability and configuration of growth cone microtubules
(Hur et al., 2011). However, abnormal CRMP2 hyperphosphory-
lation is an early event in AD progression (Cole et al., 2007) and
occurs downstream of APP, but neither excessive Aβ42 peptide
nor neurotoxicity alone are sufficient to promote it (Williamson
et al., 2011). CRMP2, hyperphosphorylated at Thr509, Ser518,
and Ser522, is also present in NFTs (Gu et al., 2000). With
axonal growth cones being dynamic extensions of developing
axons that seek appropriate synaptic targets, it is plausible that
hyperphosphorylated forms of CRMP2 that are evident in AD
may represent a blockade of such growth mechanisms in dys-
trophic/swollen neurites.
In conclusion, the increase in antioxidative enzymes BLVRA,
PRX3 and -6 as well as generally neuroprotective 14-3-3 pro-
teins is likely driven either by IL-18 itself or by induction of
OS (Figure 6). DDAH2 increases at a later time-point suggest
increased nitrosative stress, and reduced DJ-1 increased mito-
chondrial stress, which combined to Aβ production may lead to
activation of caspase-1 and apoptosis. Increased TIMP2 as well as
decreased ENOA and 14-3-3ε may indirectly lead to increased Aβ
accumulation, whereas increased SEPT2 may enhance Aβ aggre-
gation. Changes in CRMP2 phosphorylation suggest impaired
interactions with tubulin. The most interesting novel targets were
examined in AD brain samples, where DDAHr (about 55 kD)
was increased in frontal lobes of AD patients and general lev-
els of MMP14 appeared to be decreased with this number of
repeats. The role of SEPT2 in AD requires further studies. The
SH-SY5Y findings are in line with our earlier studies, in which
we have shown that IL-18 can induce several time-dependent
protein changes that have a role in the pathogenesis of AD includ-
ing NFT and Aβ-plaque formation (Ojala et al., 2008; Sutinen
et al., 2012). Further, in the present study increased antioxida-
tive enzymes seems to be followed by APP processing to Aβ
(Sutinen et al., 2012). IL-18 also increased concentration depen-
dently caspase-1 expression, indicating initiation of the apoptotic
pathway. Whether APP processing to Aβ in relation to OS or its
regulating enzymes is a cause or a consequence of the activation of
apoptotic pathway in neurons requires further studies. However,
in aged normal human neurons especially, the poorly functioning
defense systems may lead to apoptosis and/or enhanced pro-
cessing of APP to Aβ. Overall, our work strongly suggests that
increased IL-18 plays an important role in AD, particularly in
overlapping the biological underpinnings of the diseases that
increase AD risk, such as obesity, type-2 diabetes and depression
as well as when wider AD risk gene alleles are present.
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